<DOC>
	<DOCNO>NCT02537548</DOCNO>
	<brief_summary>This phase II trial study well retroperitoneal lymph node dissection ( RPLND ) work treat patient stage I-IIa testicular seminoma . The retroperitoneum space body behind intestine typically first place seminoma spread . RPLND surgery remove lymph node area treat testicular seminoma may experience few long-term toxicity , second cancer , cardiovascular disease , metabolic syndrome ( pre-diabetes ) , lung disease .</brief_summary>
	<brief_title>Retroperitoneal Lymph Node Dissection Treating Patients With Stage I-IIA Testicular Seminoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess recurrence free survival ( RFS ) 2 year RPLND RPLND use first line treatment patient testicular seminoma low volume ( = &lt; 2cm ) retroperitoneal disease . SECONDARY OBJECTIVES : I . Estimate percent patient , treatment RPLND , avoid external beam radiotherapy ( XRT ) systemic chemotherapy ( CTX ) seminoma . II . Assess complication associate primary RPLND seminoma . OUTLINE : Patients undergo RPLND . After completion study treatment , patient follow 1 month , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Seminoma</mesh_term>
	<criteria>Stage IIA pure seminoma OR stage I pure seminoma isolated retroperitoneal relapse Lymphadenopathy retroperitoneum : least one lymph node 12 cm great dimension , lymph node &gt; 2 cm great dimension , 2 lymph node 12 cm great dimension Axial imaging lymphadenopathy within 6 week date RPLND Retroperitoneal lymphadenopathy must within RPLND template If borderline lymphadenopathy , define large retroperitoneal lymph node measure 0.90 0.99 cm great dimension , abdominal compute tomography ( CT ) scan repeat ( recommend interval 6 8 week ) ; lymph node must demonstrate growth &gt; = 1.0 cm great dimension Biopsy require , though biopsy retroperitoneal node ( ) obtain , pathology must consistent pure seminoma Chest imaging ( xray , CT magnetic resonance image [ MRI ] ) negative metastasis 6 week prior date RPLND Primary tumor excise radical inguinal orchiectomy pathology consistent pure seminoma negative surgical margin Normal serum alpha fetoprotein ( AFP ) , betahuman chorionic gonadotropin ( HCG ) , lactate dehydrogenase ( LDH ) ( per local laboratory assay ) within 14 day RPLND Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Ability understand willingness sign write informed consent Platelet count &gt; 150,000 International normalize ratio ( INR ) &lt; 1.3 Normal partial thromboplastin time ( PTT ) per local laboratory assay Second primary malignancy History receive chemotherapy radiotherapy Patients receive investigational agent ( ) Any history serum AFP elevation ( include prior orchiectomy ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>